Originally published 2020-07-09.
The key facts first: in July 2020 researchers in Brazil reported that a man known as the "São Paulo patient" had shown no detectable HIV for more than 15 months after stopping all treatment. He had earlier received an intensified mix of antiretroviral drugs plus nicotinamide, a form of vitamin B3. Headlines called it the first HIV cure by drugs alone. That hope did not last: in November 2020 the virus came back, and he restarted treatment. The case is still interesting to scientists, but it is not a cure, and no drug-only cure for HIV exists today.

The São Paulo case was presented at the AIDS 2020 conference, held online in July 2020 because of the pandemic.
What doctors reported in July 2020
The patient was diagnosed with HIV in October 2012, at the age of 35. At one point his viral load rose above 20,000 copies, which showed he was not one of the rare "elite controllers" whose immune systems naturally keep the virus in check. On standard treatment his virus was suppressed, and after more than two years of stable results he joined a clinical trial at the Federal University of São Paulo in September 2015.
In March 2019, under close medical supervision, he stopped taking HIV medication altogether. At the AIDS 2020 conference the study leader, Dr Ricardo Diaz, reported that more than 15 months later tests still found no HIV genetic material in his blood, and his antibody levels had fallen so far that a rapid HIV antibody test turned negative. Diaz was careful but hopeful: "This patient might be cured."
The treatment: what was in the regimen
The idea behind the trial was to hit the virus harder than usual and try to flush it out of hiding. HIV can lie dormant inside long-lived immune cells, a hidden pool called the reservoir. Standard drugs stop new copies being made but cannot reach this dormant virus, which is why treatment normally has to continue for life.
For 48 weeks, the São Paulo patient took his usual three-drug combination plus two extra antiretrovirals, dolutegravir and maraviroc, and nicotinamide. Nicotinamide is not an "enhanced" vitamin, as some early reports suggested; it is simply one of the ordinary forms of vitamin B3. Researchers were interested in it because laboratory work suggested it might help push dormant HIV out of hiding, where it could be targeted.
After the 48 weeks he returned to his standard regimen, and only later stopped treatment completely. Five participants received this particular intensified combination, and he was the only one who stayed free of detectable virus after stopping.
A man appears to have been cured of HIV with a relatively cheap, non-toxic combination of drugs. Dr Andrea Savarino, one of the study researchers, talks to aidsmap's Gus Cairns & Liz Highleyman.
— NAM Publications (@aidsmap) July 7, 2020
aidsmap exclusive report from #AIDS2020Virtual https://t.co/e4kwBdu3KG pic.twitter.com/Z6xQ02FOi9
Why experts were cautious from the start
Many HIV specialists greeted the announcement with interest and scepticism in equal measure. Dr Jonathan Stoye of the Francis Crick Institute in London noted that, if confirmed, it would be the first drug-only cure, but that earlier attempts to intensify treatment had not pointed towards a cure. He was frustrated by the limited data on the patient's viral status and by the lack of a convincing explanation for how vitamin B3 might work. His verdict was short: "I am not convinced."
Dr Andrea Savarino of Italy's National Institute of Health, a co-investigator, was also measured. He hoped the case would encourage further research but warned that "the result is highly likely not to be reproducible." Other researchers, including Dr Steven Deeks of the University of California, San Francisco, suggested the man might simply have been unusually lucky with ordinary treatment.
The caution had a sound basis. A small number of people stay in remission for months or even years after stopping treatment, so a single long gap is not proof that the virus has gone. One success among five participants is also far too few to show that the regimen caused it.
What happened next: the virus returned
On 10 November 2020, about 72 weeks after he stopped treatment, the man developed fever, chills, headache and diarrhoea. Tests showed a viral load above 6,300 copies, and his HIV antibodies began rising again. He restarted a standard dolutegravir-based regimen in early December 2020, and by 1 January 2021 his virus was undetectable once more.
The returning virus was genetically different from his original strain in some key proteins. Diaz's team considered three explanations: the virus had changed inside his body, he had been infected again with a new strain, or an older strain from a past dual infection had re-emerged. As reported by aidsmap, sequencing was continuing to tell rebound and reinfection apart. Either way, the man was once again living with HIV and taking treatment.
How it compares with the Berlin and London patients
Only a handful of people are considered cured of HIV, and all of the best-known cases followed stem cell or bone marrow transplants given to treat blood cancers, not HIV itself.
- Timothy Ray Brown, the "Berlin patient", received transplants in 2007 and 2008 from a donor carrying CCR5-delta-32, a natural genetic variant that makes cells resistant to most HIV strains. He remained free of HIV until his death from a return of leukaemia in 2020.
- Adam Castillejo, the "London patient", diagnosed with HIV in 2003, had a bone marrow transplant in 2016 to treat stage IV Hodgkin's lymphoma. His German donor also carried CCR5-delta-32. His remission was reported in 2019, and he revealed his identity in March 2020.
Since then a few more people, sometimes named after the cities where they were treated, have been reported in long-term remission after similar transplants. These procedures carry a serious risk of complications and death, so they are used only when a patient needs a transplant for cancer. They are not an option for the millions of people living with HIV. That is exactly why a drug-only approach like the one tried in São Paulo attracted so much attention.
Living with HIV today
The absence of a cure should not hide how much has changed. According to the World Health Organization, HIV has claimed more than 44 million lives since the epidemic began in the early 1980s, and around 41 million people are living with the virus, most of them in Africa.
Modern antiretroviral therapy turns HIV into a manageable long-term condition. People who are diagnosed early and stay on treatment can expect to live long and healthy lives, with a life expectancy close to that of people without HIV in countries with good access to care. Someone on treatment whose viral load is undetectable does not pass the virus to sexual partners, a principle known as "undetectable equals untransmittable", or U=U.
The biggest challenges now are testing, access and staying on treatment, especially in poorer countries, where hundreds of thousands of people still die of HIV-related illness each year. Anyone with questions about testing or treatment should talk to a doctor or a local sexual health clinic.
Why the case still matters
Although the São Paulo patient was not cured, his story taught useful lessons. It showed how carefully any "cure" claim must be checked over long periods, why a negative antibody test is not proof of eradication, and how difficult it is to clear the hidden reservoir. Researchers continue to test ways to wake and kill dormant virus, gene-editing approaches, long-acting injections and therapeutic vaccines.
A practical cure that works for most people may still be years away. Until then, the most powerful tools remain testing, prompt treatment and prevention measures such as PrEP, which together have already transformed what an HIV diagnosis means.
Sources: aidsmap: São Paulo patient experiences apparent viral rebound a year and a half after stopping HIV treatment; Science Media Centre: expert reaction to reports of long-term HIV remission; Wikipedia: Adam Castillejo; World Health Organization: HIV and AIDS fact sheet.

COMMENTS